Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For patients with leukemia or lymphoma:
- People who have been diagnosed with leukemia or lymphoma that has come back or has not responded to previous treatment, and who are scheduled to receive a type of treatment called CAR T-cell therapy at one of the participating hospitals
- The CAR T-cell treatment program the person is enrolled in must allow their data to be shared for this study
- People aged 5 to 35 years old
- People who have a caregiver (such as a parent or close family member) who is willing to complete assessments about them as part of the study
- People under 18, or older if needed, must have a caregiver who can help set up a suitable environment for remote (online) assessments
- People who can speak and understand English or Spanish
- People who have access to a computer or tablet with a camera and an internet connection
- The person themselves, or their parent or legal guardian, must be willing and able to sign a written consent form
For caregivers taking part:
- People aged 18 or older who are a caregiver for a patient meeting the criteria above
- People who can speak and read English or Spanish
- People who have access to a computer or tablet
- Caregivers of children under 18 (or older if needed) must be willing to help set up a suitable environment for remote assessments
- People who are willing and able to sign a written consent form
Who may not be able to join:
- Patients who have a pre-existing intellectual disability that affects all areas of thinking and learning (for example, Down Syndrome)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pamela L Wolters, Ph.D., National Cancer Institute (NCI)
Phone: (240) 760-6970
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To evaluate changes in working memory in children and young adults with relapsed/refractory leukemia or lymphoma at 12 months post CAR T-cell therapy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.